2015/02/26
      Obtains Commitment from 
    
      “We are proud to partner with 
      
      “This capital commitment will be instrumental in driving value for our      startups as they advance breakthrough applications in genomics,” said      
      Illumina Accelerator is the world’s first business accelerator focused      solely on creating an innovation ecosystem for the genomics industry. It      provides select startups with seed investment, business guidance, access      to Illumina’s sequencing systems and reagents, and fully operational lab      space in the 
      Applications for Illumina Accelerator’s Spring 2015 funding cycle are      due by 
About Illumina, Inc.
Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.
      About 
      
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: 
      Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer      Temple
858-882-6822
pr@illumina.com    


